디에이치바이오

비상장계속사업자

DH Bio Co., Ltd

강태훈

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

디에이치바이오

Business Reg. No. 2288702174 · CEO 강태훈

I.Investment Overview

Target디에이치바이오 (2288702174)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명디에이치바이오
영문명DH Bio Co., Ltd
대표자강태훈
사업자등록번호2288702174
법인등록번호1544110038972
설립일2021.05.28

V.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW215.92021759.32022525.82023352.42024
영업이익100M KRW-16.32021-14.42022-63.42023-13.72024
순이익100M KRW-17.42021-14.72022-139.32023-15.22024
Item2024202320222021
자산총계113.4억원112.3억원275.9억원195.4억원
부채총계51억원34.7억원59.1억원13.9억원
자본총계62.4억원77.6억원216.8억원181.6억원
매출액352.4억원525.8억원759.3억원215.9억원
영업이익-13.7억원-63.4억원-14.4억원-16.3억원
순이익-15.2억원-139.3억원-14.7억원-17.4억원

VI.Financial Ratios

FY2024 basis

-3.88%

영업이익률

-4.32%

순이익률

-13.42%

ROA

-24.39%

ROE

81.73%

부채비율

55.03%

자기자본비율

VII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

디에이치바이오 투심보고서 | Alpha Lenz